2 completed, 1 suspended, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 2 | Suspended 1, Withdrawn 1 |
Follow RPh201: new trials by email Literature Review of RPh201 trials Research Report on RPh201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease RPh201, Placebo - Mild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease | Phase 2 | Completed | Regenera Pharma Ltd | 83 | 2018-03-01 | 2020-04-30 |
| Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Completed | Regenera Pharma Ltd | 22 | 2014-02-01 | 2020-03-19 |
| The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study RPh201, Saline - Chronic Vegetative State | Phase 1 | Suspended | Hadassah Medical Organization | 10 | 2012-09-01 | 2018-02-06 |
| The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements RPh201, saline - Chronic Vegetative State | Phase 1 / Phase 2 | Withdrawn | Hadassah Medical Organization | 2011-10-01 | 2015-09-22 |
Persistent Vegetative State (2) · Alzheimer Disease (1) · Dementia (1) · Optic Nerve Injuries (1) · Optic Neuropathy, Ischemic (1)
Hadassah Medical Organization (2) · Regenera Pharma Ltd (2)
Israel (2) · Canada (1)
Sharon Cohen, MD (1) · Tamir Ben-Hur, MD PhD (1) · Zvi Segal,, MD (1)